2022 China health industry white paper – medicine and Biotechnology From Yikai capital
The following is the 2022 China health industry white paper – medicine and Biotechnology From Yikai capital recommended by recordtrend.com. And this article belongs to the classification: Medical health, research report.
Core view
1. Since 2021, the state has issued a large number of new regulations and policies in many fields such as medical services, medicine and equipment, medical security and Listing Supervision, and strictly enforced the laws in key regulatory areas of the medical and pharmaceutical industry. Driven and guided by a number of policies, such as the normalization of national drug volume procurement, the “dual channel” of medical insurance negotiation, and drug R & D guided by clinical value, domestic pharmaceutical enterprises have gradually changed to innovation driven.
2. 2021 is a year of frequent achievements in innovative drugs in China. Many biomedical enterprises such as Zejing biology, Yasheng medicine, kangfang biology and tengshengbo medicine ushered in the first commercial new drugs. The types and indications of domestic approved drugs are also gradually diversified. The first ADC drug independently developed by Chinese local enterprises, two car-t cell therapy drugs and the first new crown neutralizing antibody combination therapy have been listed one after another. Many biotech companies in China have also begun to realize scale income. In the next few years, we will also witness the large-scale commercial application of AI pharmaceutical industry, cell therapy, ADC, synthetic biology and other high-tech tracks.
3. In the secondary markets of A-share, Hong Kong stock and US stock, the stock market performance of biomedical companies in 2021 was full of twists and turns. The annual stock prices of nearly 21 biomedical enterprises in the science and Innovation Board fell. The Chinese concept companies listed in the US stock market were extremely unstable due to regulatory policies, while the biomedical enterprises listed in Hong Kong stock continued to break. The continuous correction of the valuation of biomedical enterprises in the secondary market has triggered the pessimistic expectation of the primary market for the biomedical industry, which is bound to have a great impact on the primary market financing of the biomedical industry in 2022.
4. In 2022, the capital will focus on: gene therapy, nucleic acid drugs, cell therapy, double antibodies, ADC, upstream and downstream raw materials, synthetic biology.
If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.
RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.
